Starting with the ECPKA detection method, we are developing a companion diagnosis (XDX-01) for powering the cancer immunotherapy. KNAX and Xylonix are working together to jointly scale the manufacturing of XDX-01 and conduct broader clinical validation studies.

Collaborating with RIChBiDiT, our pipelines are now expanded to specific cancer and infectious disease diagnostics. In particular, we are striving to develop diagnostic technology that effectively and rapidly detect COVID-19 Pandemics.


#303, World Trade Tower, 511, Yeongdong-daero, Gangnam-gu, Seoul

TEL : +82-2-551-7700

FAX : +82-2-551-7701



#D-1414, Technovally
U1 center, 947,
Hanam-daero, Hanam-si, Gyeonggi-do, 12982, Republic of Korea

TEL : +82-31-5180-3184

FAX : +82-31-5180-3185


IP holdings

KNAX Singapore PTE LTD in Singapore

BGX Life Science

(wholly owned subsidiary):

61, Oriental Medicine Expo-ro, Jecheon-si, Chungbuk

© Copyright KNAX Ltd. All Rights Reserved